Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6188
IPSCIO Record ID: 612
Patent Rights means any of the following the US patent application (60/540,186, titled Novel Interstitial Therapy For Immediate Symptom Relief And Chronic Therapy In Interstitial Cystitis) disclosing and claiming the Inventions, filed by Inventors and assigned to University.
IPSCIO Record ID: 5917
IPSCIO Record ID: 29423
UracystÂ® Test Kit is a patented technology for the diagnosis and treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall.
And whereas Licensee is desirous of obtaining from Licensor the methods and technical know-how and the right and license to market, distribute and sell the Products (as such term is hereinafter defined) in the Territory (as such term is hereinafter defined), upon the terms and subject to the conditions hereinafter set forth. Methods and Technical Know-How and Grant of Licenses Subject to the provisions of this Agreement and for the Term hereinafter specified, Licensor hereby covenants and agrees to provide Licensee with the Methods and Technical Know-How necessary to enable Licensee to obtain regulatory approval for the Products in the Territory. All costs related to such regulatory approval applications shall be the obligation of Licensee. Methods and Technical Know-How materials, methods and other regulatory documents per Appendix 1 will be supplied at Licensor's cost. Subject to the provisions of this Agreement and for the Term hereinafter specified, Licensor hereby grants to Licensee the exclusive right and license, even as to Licensor, to develop, market, promote, offer to sell, sell, have sold, distribute, import, grant sublicenses, or otherwise dispose of Products in the Field in the Territory.
Licensed Technology Licensee, its consultants, and/or the FDA shall have rights of access to any and all information, including, but not limited to, trade secrets and Methods and Technical Know-How necessary to secure regulatory approvals. Trade Names and Trademarks Licensee shall have the right to sell the Products in the Territory under its own trade name and trademarks. Such trade names and trademarks, including any goodwill belonging to them, shall be the exclusive property of Licensee. Licensee shall have the right, but not the obligation, to use the trade name and/or trademark UracystÂ® for use in the Territory. Licensor shall retain the UracystÂ® trade name outside the Territory. Licensee may only grant sublicenses to third parties in order to import, market, promote, distribute and sell the Products in the Territory, provided that the licenses granted to such sub-licensees are not inconsistent with the licenses granted to Licensee.
IPSCIO Record ID: 4644
Such license is non-exclusive; provided that, between the six-month anniversary of the Effective Date and the 12-month anniversary of the Effective Date, the Licensee will have the right, at its option, to convert such non-exclusive license to an exclusive license for the remaining term of the Agreement, subject only to certain specified existing sublicenses.
The rights are to commercially compound a patented combination of alkalized lidocaine and heparin compounded formulation, for the prevention or treatment of disorders of the lower urinary tract from the Licensor. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700. The patented formulation first became available in 2011 as a compounded drug.
IPSCIO Record ID: 1167